Acasti pharma reports fiscal year 2023 operational results

Laval, quÉbec, june 23, 2023 /prnewswire/ -- acasti pharma inc. ("acasti" or the "company") (nasdaq: acst), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced financial and operational results for the fiscal year ended march 31, 2023. recent highlights united states food and drug administration (fda) has confirmed the 505(b)(2) regulatory pathway for gtx-104 and that the gtx-104-002 pk study may have met the criteria for a scientific bridge.
ACST Ratings Summary
ACST Quant Ranking